Sugi Predict

Sugi Predict / Compounds / SCHEMBL5222098

SCHEMBL5222098

SCHEMBL5222098

CCc1cc(NC(=O)NC(C)(C)CCN2CC(Oc3ccc(Cl)cc3)C2)on1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ MAPK14 Q16539 3/20 0.38
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CNR2 P34972 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ USP30 Q70CQ3 2/20 0.35
▸ CSF1R P07333 2/20 0.34
▸ FLT3 P36888 2/20 0.34
▸ ACACB O00763 2/20 0.34
▸ PDGFRB P09619 1/20 0.34
▸ KIT P10721 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ FAAH O00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5222441 0.86 CSF1R (0.39) MAPTKMT2AMEN1TDP1CNR2
SCHEMBL5224271 0.80 MEN1 (0.35) MAPTMAPK14KMT2AMEN1TDP1
SCHEMBL5225328 0.79 POLB (0.50) MAPTKMT2AMEN1LMNA
SCHEMBL5223671 0.78 CYP3A4 (0.48) MAPTMAPK14KMT2AMEN1CNR2
SCHEMBL5222998 0.77 ALDH1A1 (0.47) MAPTKMT2AMEN1LMNAESR1
SCHEMBL5223189 0.77 CCR3 (0.42) MAPTKMT2AMEN1LMNA
SCHEMBL5222409 0.77 CYP3A4 (0.44) MAPTMAPK14KMT2AMEN1ESR1
SCHEMBL5218302 0.72 ALPG (0.38) HTR2C
SCHEMBL5333712 0.68 MAPT (0.36) MAPTMAPK14KMT2AMEN1ACACB
SCHEMBL5339678 0.67 HTR2A (0.36) MAPTMAPK14KMT2AMEN1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043013-A1 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases LE GRAND DARREN M 2007-02-22 — — US claimed
EP-1663966-B1 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES NOVARTIS AG (CH) 2007-06-20 — — EP disclosed
US-20070043013-A1 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases LE GRAND DARREN M 2007-02-22 — — US disclosed
EP-1663966-A1 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES Novartis AG (CH) 2006-06-07 — — EP disclosed
WO-2005026113-A1 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES NOVARTIS AG (CH) 2005-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043013-A1 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases CCR1, CCR3, CCR9 MAPT 4418/4885MAPK14 2818/4885KMT2A 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.